Marc Schermerhorn (Boston, USA) discusses the three-year results of an analysis on the long-term survival of Nellix EVAS system (Endologix) IDE trial patients vs. a cohort of EVAR patients. The study found that EVAS is associated with higher long-term survival, with a 41% difference in overall mortality rates between the two cohorts—a number that increases to 50% for patients with >5.5cm aneurysm diameters.
Most read
Features
Profiles
